Collectionner le produit
Détails du produit
Application
Synonyms
MS4A1, CD20, MS4A-1
Source
Fluorescent Human CD20 Full Length Protein-VLP (CDP-HF2P8) is expressed from human 293 cells (HEK293). It contains AA Met 1 - Pro 297 (Accession # NP_068769.2).
Predicted N-terminus: Met 1
Molecular Characterization
This protein carries a GFP tag.
*The isotype control of empty/mock VLP (Cat. No. VLP-NF2P4) is sold separately and not included in protein, you can follow the link for product information.
Structure
Virus-like particles (VLPs) are protein particles that mimic the shape of viruses but lack a viral genome, and incorporating transmembrane proteins on the external surface.
Synthesis Process
Envelope virus-like particles (eVLPs) are produced by co-expressing target membrane proteins with viral structural proteins in mammalian cells, enabling native embedding of membrane proteins into the lipid bilayer during VLP budding. This approach preserves authentic conformation, post-translational modifications, and orientation, while creating a completely detergent-free environment with repetitive multivalent display and strong immunogenicity making them ideal for immunization, binding assays in antibody discovery and screening (ELISA), and cell-based assays such as FACS, etc.
Conjugate
GFP
Excitation source: 488 nm spectral line, argon-ion laser
Excitation Wavelength: 488 nm
Emission Wavelength: 530 nm
Purity
>95% as determined by SEC-HPLC.
Formulation
The VLPs are highly immunogenic, so the immunization strategy should be optimized (antigen dose, regimen and adjuvant).
Supplied as 0.2 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Shipping
This product is supplied and shipped with dry ice, please inquire the shipping cost.
Storage
Please protect from light and avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- The product MUST be stored at -70°C or lower upon receipt;
- -70°C for 12 months under sterile conditions.
ACRO Quality Management System
Les clients ont également consulté
Affichage des données
SEC-HPLC
The purity of Fluorescent Human CD20 Full Length Protein-VLP (Cat. No. CDP-HF2P8) was greater than 95% as determined by SEC-HPLC.
Bioactivity-ELISA
Immobilized Fluorescent Human CD20 Full Length Protein-VLP (Cat. No. CDP-HF2P8) at 5 μg/mL (100 μL/well) can bind Rituximab biosimilar (Cat. No. CD0-M36) with a linear range of 0.2-3 μg/mL (QC tested).
Protocol
Immobilized Fluorescent Human CD20 Full Length Protein-VLP (Cat. No. CDP-HF2P8) at 5 μg/mL (100 μL/well) can bind Ofatumumab with a linear range of 0.2-3 μg/mL (QC tested).
Protocol
Bioactivity-FACS
2e5 of anti-CD20 (ofatumumab) CAR-293 cells were stained with 100 μL of 10 μg/mL of Fluorescent Human CD20 Full Length Protein-VLP (Cat. No. CDP-HF2P8) and negative control protein respectively. GFP signal was used to evaluate the binding activity (QC tested).
Protocol
Identity-DLS
The mean peak Radius of VLP is 50-70 nm with more than 95% intensity as determined by dynamic light scattering (DLS).
Avis des utilisateurs Publier un commentaire
Introduction de fond
Progrès de frontière
Progrès du développement médicamenteux- Nom anglais：
B-lymphocyte antigen CD20
- Catégorie：
- Nombre de médicaments répertoriés：
35 Détails
- Nombre de médicaments cliniques：
132 Détails
- Étape de développement la plus élevée：
Approved
Contact Us
Drug Candidate Licensing
